Changes in mOS versus sample size of treatment groups in pivotal trials of drugs for 1L treatment of advanced PDAC

Gyawali B, Booth CM. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients. Lancet Oncol.